Neupogen (filgrastim) Market Report 2026

Neupogen (filgrastim) Market Overview

• The Neupogen (filgrastim) market growth in the historic period has been driven by growth in chemotherapy utilization, high infection risk in neutropenic patients • Market expansion is supported by increasing cancer incidence, expansion of biosimilar adoption • Growth Driver: Rising Diseases Prevalence Boosts Neupogen Market Growth By Enhancing Immunity • Market Trend: Innovative Filgrastim Biosimilars Enhance Affordability And Accessibility For Chemotherapy-Induced Neutropenia Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neupogen (filgrastim) Market?

Neupogen (filgrastim) is a recombinant granulocyte colony-stimulating factor (G-CSF) that stimulates the production of white blood cells in the bone marrow. It is used to prevent infection in patients with neutropenia caused by chemotherapy, bone marrow transplantation, or certain medical conditions. The main drug types of neupogen (filgrastim) are biologic and biosimilar. Biologic drugs are derived from living organisms and involve complex manufacturing processes to produce targeted therapeutic effects. Its indications include chemotherapy-induced neutropenia, chronic neutropenia, and others. These are distributed by various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Neupogen (filgrastim) Market Growth Forecast?

The neupogen (filgrastim) market size is expected to see strong growth in the next few years. It will grow to $1.81 million in 2030 at a compound annual growth rate (CAGR) of 5.2%. The growth in the forecast period can be attributed to increasing cancer incidence, expansion of biosimilar adoption, growth in outpatient oncology services, improved access to biologic therapies, focus on infection prevention. Major trends in the forecast period include rising use of supportive care in oncology, expansion of chemotherapy-induced neutropenia management, increased adoption of biologic growth factors, shift toward outpatient neutropenia treatment, growing use of biosimilar alternatives.

Global Neupogen (filgrastim) Market Segmentation

1) By Drug Type: Biologic, Biosimilar 2) By Indication: Chemotherapy Induced Neutropenia, Chronic Neutropenia, Others 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Are The Drivers Of The Neupogen (filgrastim) Market?

An increase in the prevalence of various diseases is expected to propel the growth of the neupogen (filgrastim) market going forward. Diseases are abnormalities in the structure or function of the body that produce specific symptoms or affect specific locations, often caused by infections, genetics, environmental factors, or lifestyle choices. The rising prevalence of various diseases is driven by factors such as aging populations, sedentary lifestyles, increasing pollution levels, poor dietary habits, and the global spread of infectious pathogens. Neupogen (filgrastim) addresses the complications of chemotherapy-induced neutropenia by stimulating the production of neutrophils, thereby enhancing the immune system's ability to combat infections in patients with weakened immunity. It is instrumental in reducing hospitalization rates, managing infection risks, and supporting uninterrupted cancer treatment regimens for patients undergoing intensive therapies. For instance, in April 2024, according to Allergy UK, a UK-based national charity, more than 21 million people in the UK are affected by allergies, which became the most commonly reported chronic health condition in 2022, and projections indicate that by 2026, half of Europe's population will experience at least one allergy. Additionally, in June 2022, according to the data published by the Macmillan Cancer Support, a UK-based cancer charity, the number of people living with cancer reached 3 million in 2022 and is projected to rise to nearly 3.5 million by 2025 and 4 million by 2030 in the UK. Therefore, the increase in prevalence of various diseases is driving the growth of the neupogen (filgrastim) industry. Government initiatives for research and development in healthcare are expected to propel the growth of the growth of the neupogen (filgrastim) market going forward. Government initiatives refer to specific actions, programs, policies, or projects undertaken by government authorities at various levels (local, regional, national, or international) to address specific issues, achieve certain goals, or create positive changes in society. Several government authorities are initiating various healthcare initiatives to support various aspects including neupogen (filgrastim). For instance, in May 2023, according to the Department of Health and Social Care, a UK-based government authority, the UK government announced a $749.09 million (£650 million) “Life Sci for Growth” package to boost the life sciences sector. The package includes $139.44 million (£121 million) to accelerate commercial clinical trials, $177.47 million (£154 million) to expand the UK Biobank’s capabilities, and incentives up to $288.11 million (£250 million) to bring pension-fund investment into the sector. Therefore, Government initiatives for research and development in healthcare drives the neupogen (filgrastim) industry.

Key Players In The Global Neupogen (filgrastim) Market

Major companies operating in the neupogen (filgrastim) market are Amgen Inc.

Global Neupogen (filgrastim) Market Trends and Insights

Major companies operating in the neupogen (filgrastim) market are increasingly focusing on developing innovative products as filgrastim biosimilars to provide a cost-effective and accessible alternative for treating chemotherapy-induced neutropenia. Filgrastim biosimilars are biologic medications that closely mimic the original filgrastim (Neupogen) in terms of safety, efficacy, and structure, used primarily to stimulate the production of neutrophils in patients undergoing chemotherapy to prevent neutropenia. For instance, in September 2024, Tanvex BioPharma, a U.S.-based biopharmaceutical company, received approval from the U.S. Food and Drug Administration (FDA) for Nypozi (filgrastim-txid), a biosimilar referencing Amgen’s Neupogen. Nypozi became one of three biosimilars cleared by the FDA on the same day, contributing to a total of 55 biosimilars approved in the United States as of June 2024. It is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs.

Regional Insights

North America was the largest region in the neupogen (filgrastim) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Neupogen (filgrastim) Market?

The neupogen (filgrastim) market consists of sales of formulations, pre-filled syringes, vials for injection, and long-acting pegylated G-CSF derivatives. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neupogen (filgrastim) Market Report 2026?

The neupogen (filgrastim) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neupogen (filgrastim) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.